“Individual patient data from dose escalation studies will be available on a rolling basis, and we anticipate seeing efficacy results later this year.”

In context

“lutekizumab. Our extended half-life TL1A antibody will also be evaluated in combination with SKYRIZI, with a phase 2b dose-ranging study in Crohn's and ulcerative colitis beginning later this year. Separately, a phase two study is underway to evaluate our TREM1 antibody as a monotherapy in Crohn's disease. Data from this study will be available later this year and will help inform our combination strategy for this molecule. The phase 1b trial for ABBV 319, our anti-CD19 ADC with a steroid payload, is now underway, and we will soon begin dosing patients with our in vivo CD19 CAR T, ABBV 619. These B cell depleting approaches have the potential to become transformative modalities to reset the immune system and provide deep, durable, drug-free remission for patients with autoimmune diseases. Individual patient data from dose escalation studies will be available on a rolling basis, and we anticipate seeing efficacy results later this year. Several additional immunology assets will also be entering the clinic this year, including an extended half-life anti-IL-23 antibody and an oral peptide IL-23 inhibitor. Moving to oncology, progress continues with our next-generation cMet ADC tmAbA. Strong data have been observed in late-line colorectal cancer, as both a monotherapy and in combination with bevacizumab. Therefore, we will be initiating a phase three study this year in an all-comers population in combination with VEV. Dose optimization continues for tmAbA in non-small cell lung cancer, where both EGFR wild-type and EGFR mutant populations are being evaluated. Data from these studies will be available next year, informing our phase three path. In pancreatic cancer, tmAbA will be studied in combination with different regimens”